Rates of Return in Biotech IPOs by Market Cap
This article was originally published in Start Up
Executive Summary
Though the market for biotech IPOs has been largely dormant recently, we wondered how biotechs that received the highest market caps in recent IPOs fared against their smaller-cap counterparts on delivering rates of return to private investors.